首页> 外文期刊>Risk Management and Healthcare Policy >Impact of Antimicrobial Stewardship Program on Vancomycin Usage: Costs and Outcomes at Hospital for Tropical Diseases in Ho Chi Minh City, Vietnam
【24h】

Impact of Antimicrobial Stewardship Program on Vancomycin Usage: Costs and Outcomes at Hospital for Tropical Diseases in Ho Chi Minh City, Vietnam

机译:抗菌管道方案对万古霉素的影响:越南胡志明市热带疾病的成本和成果

获取原文
           

摘要

Background:Nowadays, with the emergence of vancomycin-resistant strains, the clinical use of vancomycin has been followed closely by applying the antimicrobial stewardship program (ASP) to enhance effectiveness in treatment and reduce cost burden for patients.Methods:A descriptive cross-sectional study at the Hospital for Tropical Diseases was conducted to assess the inpatient status assigned to intravenous vancomycin and factors associated with the cost of treatment during two periods of implementing ASP, which were i) from April 1, 2016 to March 31, 2018 (previous ASP-pASP) and ii) from June 1, 2018 to March 31, 2020 (new ASP-nASP).Results:Among 1375 patients who met the sampling criteria, there were 601 and 774 patients in pASP and nASP, respectively. The rate of no improvement/mortality in the pASP was higher than that in nASP (37.10% vs 25.98%, p 0.05). The proportion of patients with two or more infection episodes in nASP is lower than that in pASP (9.83% vs 18.64%, p0.05). Besides, nASP has higher length of therapy (LOT) and higher day of therapy (DOT). The average treatment cost in the pASP is higher than that in the nASP, 1891.22 (95% CI, 1713.46-2068.98) USD vs 1775.55 (95% CI, 1576.22-1974.88) USD. There are seven factors (p0.05) that associate with the total cost of treatment (age, number of infection episodes, length of stay, discharge status, clinical department, LOT, DOT) in pASP. On the other hand, the nASP has five factors (p0.001), in which the log(LOT) and age are not as statistically significant (p=0.5127 and 0.3852, respectively) as in the pASP model.Conclusion:The implementation and improvement of the ASP at the Hospital for Tropical Diseases have initially shown benefits for patients using intravenous vancomycin. Specifically, the ASP helps to reduce treatment costs, improve patient outcomes, reduce length of stay and decrease the average daily dose of vancomycin.? 2021 Nguyen-Thi et al.
机译:背景:如今,随着万古霉素抗性菌株的出现,通过应用抗微生物管理计划(ASP)来提高治疗的有效性并降低患者成本负担的临床使用。方法:一种描述性横截面进行医院的热带疾病研究,评估分配给静脉内万古霉素的病例状况和与在2018年4月1日至2018年3月31日(以前的ASP -Pasp)和II)从2018年6月1日至3月31日,2020年3月31日(新的ASP-NASP)。结果:在1375名符合采样标准的患者中,PASP和NASP中有601和774名患者。 PASP中没有改善/死亡率的速率高于NASP(37.10%Vs 25.98%,P <0.05)。 NASP中两个或更多感染发作的患者的比例低于皮满(9.83%Vs18.64%,P <0.05)。此外,NASP具有较高的疗法(批次)和更高的疗法(点)。 PASP的平均治疗成本高于NASP,1891.22(95%CI,1713.46-2068.98)USD vs 1775.55(95%CI,1576.22-1974.88)USD。有七种因素(p& 0.05),与皮满的总治疗成本(年龄,感染发作,放电状态,临床部门,批次,点)的总成本相关联。另一方面,NASP有五个因素(P <0.001),其中日志(批次)和年龄不像PASP模型中那样与PASP模型中的统计学意义(P = 0.5127和0.3852)。结论:实施和通过静脉内万霉素的患者初始显示热带疾病的ASP在医院的ASP的改进。具体而言,ASP有助于降低治疗成本,改善患者结果,减少留下的长度并降低万古霉素的平均每日剂量。 2021 Nguyen-Thi等。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号